St. David’s HealthCare to invest $275M in Texas

St. David’s HealthCare announced plans to invest $275 million into the Central Texas healthcare infrastructure during the next two years, reports Community Impact.

St. David’s plans include a new hospital in North Austin, a $50 million expansion at St. David’s South Austin Medical Center, a $70 million expansion at St. David’s Medical Center and a $20 million investment for a new hospital in Leander.

“Very recently we’ve reached a point [at our existing facilities] where we’re at or about to exceed capacity,” said president and CEO David Huffstutler. “We work very hard to provide the best in care and service, … and I think this is largely a response to the demand we’ve seen from [the community]. They’ve specifically voted with their feet, and that’s why we have the capacity restraints we have today.”

Currently with more than 8,700 employees, the company plans to hire approximately 600 new employees at its North Austin hospital.  

St. David’s plans to invest $20 million to build an 11,200-sq.-ft. emergency department in Leander, as well as a medical office building and 80-bed hospital with mroe than 200 more employees.

“We expect that very soon we will be developing plans for the full-service hospital in that community,” Huffstutler added. “It has been good to work with the city so far."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.